Wordt geladen...
Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies
BACKGROUND. Brentuximab vedotin is an antibody-drug conjugate designed to selectively deliver monomethyl auristatin E, a microtubule-disrupting agent, to CD30-expressing cells. Brentuximab vedotin induces durable objective responses in patients with relapsed or refractory Hodgkin lymphoma (HL) after...
Bewaard in:
| Hoofdauteurs: | , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
AlphaMed Press
2012
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3425525/ https://ncbi.nlm.nih.gov/pubmed/22855426 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0133 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|